Furthermore, anti–IL-17A antibodies (such as AIN457) are currently being investigated for the clinical treatment of autoimmune diseases, including RA, psoriasis, and Crohn's disease, and therapeutic effects are starting to be reported [62]. Here, IL17A is linked to Crohn disease.